{
    "organizations": [],
    "uuid": "36573f1d1336bdc9700562f9a4aeccfeaf47f5a9",
    "author": "",
    "url": "https://www.reuters.com/article/brief-acetos-unit-launches-efavirenz-cap/brief-acetos-unit-launches-efavirenz-capsules-50mg-200mg-idUSFWN1OX0NF",
    "ord_in_thread": 0,
    "title": "BRIEF-Aceto's Unit Launches Efavirenz Capsules, 50Mg, 200Mg",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "January 2, 2018 / 5:59 PM / Updated 4 minutes ago BRIEF-Aceto's Unit Launches Efavirenz Capsules, 50Mg, 200Mg Reuters Staff \nJan 2 (Reuters) - Aceto Corp: \n* ACETO SUBSIDIARY, RISING PHARMACEUTICALS, LAUNCHES EFAVIRENZ CAPSULES, 50MG AND 200MG \n* SAYS UNIT ‍LAUNCHED GENERIC FOR EFAVIRENZ CAPSULES, AN FDA-APPROVED GENERIC VERSION OF REFERENCE LISTED DRUG SUSTIVA FROM BRISTOL MYERS SQUIBB​ Source text for Eikon: Further company coverage:",
    "published": "2018-01-02T19:57:00.000+02:00",
    "crawled": "2018-01-02T20:09:15.001+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "january",
        "pm",
        "updated",
        "minute",
        "ago",
        "unit",
        "launch",
        "efavirenz",
        "capsule",
        "50mg",
        "200mg",
        "reuters",
        "staff",
        "jan",
        "reuters",
        "aceto",
        "corp",
        "aceto",
        "subsidiary",
        "rising",
        "pharmaceutical",
        "launch",
        "efavirenz",
        "capsule",
        "50mg",
        "200mg",
        "say",
        "unit",
        "generic",
        "efavirenz",
        "capsule",
        "generic",
        "version",
        "reference",
        "listed",
        "drug",
        "sustiva",
        "bristol",
        "myers",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}